Early Alzheimer's disease research hub

Characterization of Immune Response in Participants from a Posdinemab Study

This study is looking at how a trial medicine called Posdinemab affects the body's defence system in people with early Alzheimer's disease. Researchers want to understand if and how this medicine changes the immune system. Anyone aged 18 or over, male or female, with early Alzheimer's might be able to take part.

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

This study is testing a new medicine, lecanemab, for people in the early stages of Alzheimer's disease. Researchers want to see if it's safe and helps slow down memory and thinking problems. Some people will get the medicine, and others a dummy treatment.

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

This study is looking into a new medication called MK-2214 for people with early Alzheimer's disease. Researchers want to see if it can slow down changes in the brain that cause memory and thinking problems. They will also check if it's safe for people to take.

Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

This study looks at the long-term safety and effects of a drug called ALZ-801 for people with early Alzheimer's disease who have a specific genetic make-up (APOE4/4). It's an ongoing study where all participants receive the active drug. The aim is to see how well it works and if it's safe over a longer period.

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study with a Long-Term Extension Treatment Period to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer's Disease